跳至主要内容
临床试验/NCT02587741
NCT02587741招募中早期 1 期

Comparison of Diabetes Retinopathy Among Type 2 Diabetic Patients Treated With Different Regimens: a Multicentre Randomized Parallel-group Clinical Trial

Third Affiliated Hospital, Sun Yat-Sen University1 个研究点 分布在 1 个国家目标入组 600 人开始时间: 2015年7月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
早期 1 期
状态
招募中
发起方
入组人数
600
试验地点
1
主要终点
The incidence of diabetic retinopathy

研究概览

简要总结

Diabetic retinopathy (DR) is an important cause of blindness.

详细描述

Diabetic retinopathy (DR) is an important cause of blindness, and its development of an irreversible process. DR is not only the overall progress and the level of blood sugar, and blood glucose fluctuations more closely, is the key to a smooth hypoglycemic delay DR progression.Diabetes control and complication trail(DCCT) study shows that even though glycemic control was no significant difference in blood glucose fluctuations ,DR also have a significant difference. In this study, three different glucose-lowering program for: (A) a single oral anti-diabetic drugs, (B) basal insulin and oral anti-diabetic drugs, (C) premixed insulin and oral anti-diabetic drugs for comparison. Focus on the stability and the impact of these three programs hypoglycemic long-term prognosis of the DR, and thus affect the molecular mechanisms of DR-based exploration of glucose fluctuations, to optimize blood glucose solutions, lower blood sugar steady, slow progression of DR ultimate clinical purposes.

The multi-center study is to cooperate, enrolled 600 cases of type 2 diabetes, observe the effects of different solutions on blood sugar glucose fluctuations and retinopathy, a total of 5 years of follow-up. This will be the first at home and abroad to compare the incidence of hypoglycemic effect programs on DR large multi-center, randomized, controlled clinical studies, clinical practice will optimize the treatment of type 2 diabetes theoretical and evidence-based medicine.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

年龄范围
30 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • aged 30-65;
  • diagnosed to be type 2 diabetes in accordance with the WHO diagnostic criteria in 1999 .
  • diabetes duration for 5 years or less;
  • the glycosylated hemoglobin (HbA1c) is higher than or equal to7.0% ;
  • body mass index (BMI) 20-35 kg/m2;
  • fluorescein fundus angiography (FFA) showed no diabetic retinopathy;
  • women of childbearing-age have birth control plan for 5 years plan;

排除标准

  • pregnant or lactating women;
  • diabetes autoantibodies (GAD) antibodies positive;
  • occurred state of diabetic ketoacidosis, diabetes, high permeability, diabetes lactic acidosis within a half years ;
  • aspartate aminotransferase (AST), alanine aminotransferase (ALT) 2.5 times higher than normal ceiling, and/or serum creatinine (Cr) or 133 umol/l (1.5 mg/dl);
  • hemoglobin disease history which can affect determination of HbA1c;
  • have received a coronary angioplasty, coronary artery stent implantation, coronary artery bypass surgery, there was myocardial infarction, unstable angina, and clinical significance of abnormal ecg, cerebrovascular accident, or transient ischemic attack.
  • psychiatric patients;
  • any eye eyesight < 0.1 patients (WHO blind eye disease: keratitis, need serious cataract surgery, glaucoma, uveitis, high myopia shaft > 26.5 mm, history of ocular trauma;Other ophthalmology medical history: the central vein occlusion, branch vein occlusion, wet sex senile macular degeneration, etc.;
  • in eye surgery history, history of cataract surgery, and three months; Other serious diseases, the researchers think that don't fit into the patients

研究组 & 干预措施

oral drugs

Experimental

oral anti-diabetic drugs only.metformin,start from 500mg bid,if blood glucose dose not reach the standard,added to 500mg tid→1000mg bid.if metformin reach the biggest dosage,added gliclazide modified release tablets,from 30mg qd,if blood glucose dose not reach the standard,add dosage 30mg qd→60 mg qd→90mg qd→120mg qd(max).if still not reach the target,add acarbose 50mg tid

干预措施: Metformin (Drug)

lantus

Experimental

basal insulin combine with oral drugs,started with insulin glargine 0.2 u/kg subcutaneous injection at 10pm(at 8am if patients are night workers),add dosage if glucose dose not reach the target.after that,you can add oral drugs ,as Group Oral Drugs.

干预措施: Lantus (Drug)

Novomix30

Experimental

premixed insulin combine with oral drugs,started with premixed insulin subcutaneous injection(0.4-0.6 u/kg divided into half before breakfast and dinner),and add dosage if glucose dose not reach the target.after that,you can add oral drugs ,as Group Oral Drugs .

干预措施: Novomix30 (Drug)

结局指标

主要结局

The incidence of diabetic retinopathy

时间窗: 5years

5-year incidence rate of diabetic retinopathy(%)

次要结局

  • renal failure(5years)
  • glucose fluctuation(every one year in 5years)
  • oxidative stress(every one year in 5 years)
  • cardiovascular events(5 years)

研究者

发起方
Third Affiliated Hospital, Sun Yat-Sen University
申办方类型
Other
责任方
Principal Investigator
主要研究者

Yanming Chen

Professor of Internal Medicine

Third Affiliated Hospital, Sun Yat-Sen University

研究点 (1)

Loading locations...

相似试验

Comparison of Diabetes Retinopathy Among Type 2... | 临床试验